High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200Bruce J. Giantonio, Al B. Benson, Edith P. Mitchell et al.|Journal of Clinical Oncology|2005Cited by 344
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200Bruce J. Giantonio, Al B. Benson, David E. Levy et al.|Annals of Oncology|2006Cited by 135